Revision 3
#14421
Store at -20C
877-616-CELL (2355)
877-678-TECH (8324)
3 Trask Lane | Danvers | Massachusetts | 01923 | USA
For Research Use Only. Not for Use in Diagnostic Procedures.
Applications:
W, IP
Reactivity:
H M R
Sensitivity:
Endogenous
MW (kDa):
230-280
Source/Isotype:
Rabbit IgG
UniProt ID:
#Q14524
Entrez-Gene Id:
6331
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity/Sensitivity
Source / Purification
Background
There are 9 mammalian alpha subunits, named Nav1.1-Nav1.9 (5). These alpha subunits differ in tissue specificity and biophysical functions (6,7). Seven of these subunits are essential for the initiation and propagation of action potentials in the central and peripheral nervous system while Nav1.4 and Nav1.5 are mainly expressed in skeletal muscle and cardiac muscle (8,9). Mutations in these alpha channel subunits have been identified in patients with epilepsy, seizure, ataxia, sensitivity to pain, and cardiomyopathy (reviewed in 10).
Nav1.5 is a type V alpha subunit. It is expressed primarily in cardiac muscle and is accountable for the initiation and propagation of the cardiac action potentials (11). Mutations in the SCN5A gene encoding Nav1.5 have been associated with arrhythmic cardiac diseases such as Brugada syndrome, long QT syndrome 3, and Progressive familial heart block 1A (PFHB1A) (12-15). Nav1.5 is also expressed in jejunal circular smooth muscle (HJCSM) cells. Research studies identified loss of function of Nav1.5 in 2% of patients with irritable bowel syndrome (9,16). Nav1.5 has multiple splice variants, several of which are expressed in the brain (17-18).
Background References
- Catterall, W.A. (2000) Neuron 26, 13-25.
- Yu, F.H. and Catterall, W.A. (2003) Genome Biol 4, 207.
- Isom, L.L. et al. (1994) Neuron 12, 1183-94.
- Yu, F.H. et al. (2003) J Neurosci 23, 7577-85.
- Goldin, A.L. et al. (2000) Neuron 28, 365-8.
- Plummer, N.W. and Meisler, M.H. (1999) Genomics 57, 323-31.
- Goldin, A.L. (2001) Annu Rev Physiol 63, 871-94.
- George, A.L. et al. (1992) Ann Neurol 31, 131-7.
- Ou, Y. et al. (2002) Neurogastroenterol Motil 14, 477-86.
- Meisler, M.H. and Kearney, J.A. (2005) J Clin Invest 115, 2010-7.
- Gellens, M.E. et al. (1992) Proc Natl Acad Sci U S A 89, 554-8.
- Wang, Q. et al. (1995) Cell 80, 805-11.
- Chen, Q. et al. (1998) Nature 392, 293-6.
- Schott, J.J. et al. (1999) Nat Genet 23, 20-1.
- Tan, H.L. et al. (2001) Nature 409, 1043-7.
- Beyder, A. et al. (2014) Gastroenterology 146, 1659-68.
- Wang, J. et al. (2009) Neurosci Res 64, 339-47.
- Ren, C.T. et al. (2012) Mol Cell Biochem 365, 139-48.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
W: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: Human M: Mouse R: Rat
Trademarks and Patents
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
Revision 3
